A series of 6-(4-substituted phenyl)-9-(tetrahydropyran-2-yl)purines 3-9, 6-(4-substituted phenyl)purines 10-16, 9-((4-substituted phenyl)sulfonyl)-6-(4-substituted phenyl)purines 17-32 were prepared and screened initially for their in vitro anticancer activity against selected human cancer cells (liver Huh7, colon HCT116, breast MCF7). 6-(4-Phenoxyphenyl)purine analogues 9, 16, 30-32, had potent cytotoxic activities. The most active purine derivatives 5-9, 14, 16, 18, 28-32 were further screened for their cytotoxic activity in hepatocellular cancer cells. 6-(4-Phenoxyphenyl)-9-(tetrahydropyran-2-yl)-9H-purine (9) had better cytotoxic activity (IC 50 5.4 μM) than the well-known nucleobase analogue 5-FU and known nucleoside drug fludarabine on Huh7 cells. The structure-activity relationship studies reported that the substitution at C-6 positions in purine nucleus with the 4-phenoxyphenyl group is responsible for the anti-cancer activity.
Introduction
Cancer is a major human health problem and one of the principal reasons of death in both developing and industrialized countries. Purine and purine nucleoside analogues are important anti-cancer drugs used for the treatment of both hematological malignancies and solid tumors in chemotherapy. In 1953 and 1966, among the first anticancer drugs 6-mercaptopurine and 6-thioguanine ( Fig. 1) were used as an inhibitor of nucleic acid metabolism in childhood acute lymphoblastic leukemia, respectively. [1] [2] [3] [4] Potent purine-based cyclin-dependent kinase inhibitors olomoucine, 5 roscovitine, 6 purvalanol A, B, amino-purvalanol 7 ( Fig. 2 ) and heterocyclic analogues of these compounds imidazo-pyrazines, 8 pyrazolo-pyrida- zines, 9 imidazo-pyridines, 10, 11 thieno-pyridines, 12 pyrrolo-pyrimidines, 13 pyrazolo-pyrimidines 14, 15 and triazolopyrimidines 16, 17 have been investigated as anticancer agents.
Furthermore, purine nucleosides such as fludarabine, cladribine, and pentostatine ( Fig. 3) were approved in FDA for the therapy of hematologic disorders between 1991 and 1992. 18, 19 2. Experimental
1. Chemistry
Melting points were recorded with a capillary melting point apparatus (Electrothermal 9100) and are uncorrected. NMR spectra were recorded on a VARIAN Mercury 400 FT-NMR spectrometer (400 for 1 H, 100.6 MHz for 13 C). TMS was used as internal standard for the 1 H and 13 C NMR spectra; values are given in δ (ppm) and J values are in Hz. Mass spectra were taken on Waters Micromass ZQ by using ESI+ ionization method. Elemental analyses (C, H, N) were determined on a Leco CHNS 932 instrument and gave values within ±0.4% of the theoretical values. Column chromatography was accomplished on silica gel 60 (40-63 mm particle size). The chemical reagents used in synthesis were purchased from Merck, Fluka, Sigma and Aldrich.
1. 1. 6-Chloro-9-(tetrahydro-2H-pyran-2-yl)-
9H-purine (2) 30 p-TSA (0.01 g) was added to a solution of 6-chloropurine (0.15 g, 1 mmol) in dry THF at reflux. After 3,4-dihydro-2H-pyran (0.098 g, 1.18 mmol) was added and the mixture refluxed for 15 h. After cooling to ambient temparature the reaction mixture was treated with 1 mL 25% NH 4 OH and sitirred for 5 min. The solution was evaporated in vacuo and treated with 25 mL EtOAc, washed with brine and water. The organic phase was dried over Na 2 SO 4 , the solvent was evaporated in vacuo, and recrystallized from hexane petroleum ether to yield 2 (220 mg; 95%): mp 69-71 °C (67-69 °C 30 
1. General Procedure for the Synthesis of 6-(4-Substituted Phenyl)-9-(tetrahydropyran-2-yl)-9H-purines 3-9
6-Chloro-9-(tetrahydropyran-2-yl)-9H-purine (2) was dissolved in 5 mL toluene, then K 2 CO 3 (1.5 mmol), 4-substituted phenylboronic acid (1.5 mmol) and Pd(Ph 3 ) 4 (0.05 mmol) were added. The mixture was refluxed for 12 h. The reaction mixture was concentrated in vacuo. The residue was dissolved in CH 2 Cl 2 and purified by column chromatography (EtOAC-hexane, 1:3 to 1:6). Hepatocellular carcinoma (HCC) is one of the deadly cancers and affects most of the world population. It is also the fifth most common cancer in men and seventh in women, accounting for 7% of all cancer cases, and the third most common reason of cancer-connected death worldwide, with around 700,000 new cases each year. [20] [21] Chronic liver damage is due to viral diseases, chemical exposure, environmental toxins or autoimmune diseases that are the risk factors for HCC. These conditions cause an acquired tolerance to genotoxic stress, but finally result in a cancerous case that does not respond to the mechanism of cell death. 23 The diagnosis of HCC patients is usually very poor and HCC tumors are resistant to chemotherapeutic agents. Lately, a multikinase inhibitor Sorafenib, was approved by the FDA and the EU for the treatment of hepatocellular carcinoma. 24 Sorafenib HCC Assessment Randomised Protocol (SHARP) indicated significantly improved overall survival and the time to progression by almost three months in cases with advanced HCC upon treatment with the antiangiogenic and antiproliferative agent Sorafenib. [25] [26] [27] Therefore, it is essential to discover new livercancer-specific drugs for hepatocellular carcinoma treatment.
6-Phenyl-9-(tetrahydro-2H-pyran-2-yl)-9H-purine (3)
As a result of our ongoing investigations of purine and purine nucleoside derivatives, which have displayed promising cytotoxic activity, 28 
6-(4-Trifluoromethylphenyl)-9-(tetrahydro-2H-pyran-2-yl)-9H-purine (7)
Yield 250 mg (73%), mp 164-165 °C. 1 
6-(4-tert-Butylphenyl)-9-(tetrahydro-2H-pyran-2-yl)-9H-purine (8)
Yield 230 
6-(4-Phenoxyphenyl)-9-(tetrahydro-2H-pyran-2-yl)-9H-purine (9)
Yield 220 mg (60%), mp 147-149 °C. 
1. 3. General Procedure for the Synthesis of 6-(4-Substituted Phenyl)-9H-purines 10-16
A mixture of 6-(4-substituted phenyl)-9-(tetrahydropyran-2-yl)-9H-purines (1 mmol) 3-9, Dowex 50 × 8 (H + ) (700 mg), MeOH (10 mL) and H 2 O (1 mL) was refluxed. Then the reaction mixture was filtered and washed with saturated methanolic NH 3 and MeOH. The filtrate was evaporated in vacuo, and recrystallized from EtOAc -hexane. 
6-Phenyl-9H-purine (10)

6-(4-Fluorophenyl)-9H-purine (11)
6-(4-Trifluoromethylphenyl)-9H-purine (14)
Yield 210 mg (80%), mp 221-223 °C. 1 
6-(4-tert-Butylphenyl)-9H-purine (15)
Yield 220 mg (88%), mp 291-293 °C. 1 
1. 4. General Procedure for the Sulfonylation of 6-(4-Substituted Phenyl)-9H-purines (Preparation of Compounds 17-32)
A solution of (substituted phenyl)sulfonyl chloride (2 mmol) in 5 mL CH 2 Cl 2 was slowly added to a solution of 6-(4-substituted phenyl)-9H-purines 10-16 (1 mmol) in 1 mL pyridine. The reaction mixture was stirred for 40-48 h in an ice bath. The reaction mixture was treated with 1N HCl (5 mL) and extracted with CH 2 Cl 2 . The extract was dried over Na 2 SO 4 , the solvent was evaporated in vacuo, and the residue was purified by column chromatography (hexane:CH 2 Cl 2 , 1:1). Fluorophenylsulfonyl)-6-phenyl-9H-purine (17 
9-(4-
9-(4-Trifluoromethylphenylsulfonyl)-6-(4-fluorophenyl)-9H-purine (21)
Yield 140 mg (32%), mp 214-216 °C. 1 
9-(4-tert-Butylphenylsulfonyl)-6-(4-fluorophenyl)-9H-purine (22)
Yield 80 mg (20%), mp 226-227 °C. 
9-(4-Fluorophenylsulfonyl)-6-(4-chlorophenyl)-9H-purine (23)
Yield 190 
9-(4-Fluorophenylsulfonyl)-6-(4-bromophenyl)-9H-purine (24)
Yield 110 mg (25%), mp 243-245 °C. 
9-(4-Fluorophenylsulfonyl)-6-(4-trifluoromethylphenyl)-9H-purine (25)
Yield 110 mg (26%), mp 240-242 °C. 1 
9-(4-Trifluoromethylphenylsulfonyl)-6-(4-trifluoromethylphenyl)-9H-purine (26)
Yield 140 mg (31%) mp 240-241 °C. 
9-(4-tert-Butylphenylsulfonyl)-6-(4-trifluoromethylphenyl)-9H-purine (27)
Yield 100 
9-(4-Fluorophenylsulfonyl)-6-(4-tert-butylphenyl)-9H-purine (28)
Yield 180 mg (44%), mp: 240-242 °C. 
9-(4-Trifluoromethylphenylsulfonyl)-6-(4-tert-butylphenyl)-9H-purine (29)
Yield 120 mg (26%), mp 199-201 °C. 1 
9-(4-Fluorophenylsulfonyl)-6-(4-phenoxyphenyl)-9H-purine (30)
Yield 300 mg (66%), mp 178-180 °C. 
9-(4-tert-Butylphenylsulfonyl)-6-(4-phenoxyphenyl)-9H-purine (32)
Yield 210 mg (43%), mp 157-159 °C. 
Cytotoxic Activity
1. Cells and Culture
The human primary liver cancer cell lines (Huh7, HepG2, Mahlavu and FOCUS) were grown in Dulbecco's Modified Eagle's Medium (DMEM) (Invitrogen GIBCO), with 10% fetal bovine serum (FBS) (Invitrogen GIBCO), nonessential amino acids, and 1% penicillin (Biochrome). It was incubated in 37 °C with 5% CO 2 . DMSO (Sigma) was used as the solvent for the compounds. The concentration of DMSO was always less than 1% in the cell culture medium. The cytotoxic drugs (5-FU, Fludarabine and Cladribine) used as positive controls were from Calbiochem.
Sulforhodamine B (SRB) Assay for Cytotoxicity Screening
Huh7, HCT116, MCF7, HepG2, Mahlavu, and FOCUS cells were inoculated (2000-10000 cells/well in 200 μL) in 96-well plates. The next day, the media were refreshed and the compounds dissolved in DMSO were applied in concentrations between 1 and 40 μM in parallel with DMSO-only treated cells as negative controls. At the 72nd hour of treatment with compounds 3-32 and the other drugs, the cancer cells were fixed with 100 μL of 10% (w/v) trichloroacetic acid (TCA) and kept at +4 °C in the dark for one hour. TCA fixation was terminated by washing the wells with ddH 2 O five times. Air-dried plates were stained with 0.4% sulphorhodamine B (SRB) dissolved in 1% acetic acid solution for 10 min in the dark and at room temperature. The protein-bound and dried SRB dye was then solubilized with 10 mM Tris-Base pH 8. The absorbance values were obtained at 515 nm in a microplate reader. The data were normalized against DMSO only treated wells, which were used as controls in serial dilutions. In all experiments, a linear response was observed, with serial dilutions of the compounds and the drugs.
Results and Discussion
1. Chemistry
The 6-(4-substituted phenyl)-9-[(4-substituted phenyl)sulfonyl]purine derivatives 17-32 were prepared as shown in Scheme 1. The N-9 position in the starting compound 6-chloropurine (1) was protected as the tetrahydropyran-2-yl (THP) derivative 2 30 by reacting 1 with the carbocation formed in situ from 3,4-dihydro-2H-pyran and catalytic amount of p-TSA in refluxing THF. We prepared the 6-(substituted phenyl)purines 3-9 by Suzuki coupling reaction. This coupling with 4-substituted phenyl boronic acids in toluene catalyzed by Pd(PPh 3 ) 4 gave compounds 3-9. The THP derivatives 3-9 were deprotected using wet Dowex 50 × 8 (H+) in methanol to obtain 6-(4-substituted phenyl)purines 10-16. Compounds 10-16 were N-sulfonylated with complete regioselectivity applying the same set of reaction conditions as 
2. Cytotoxic Activity and StructureActivity Relationship (SAR)
The in vitro cytotoxicity of the compounds 3-32 were initially analyzed on human cancer cells (liver Huh7, colon HCT116, breast MCF7), using a sulforhodamine B (SRB) assay. The IC 50 values for each compound were also calculated in comparison with the known cell growth Table 1 . Among the molecules synthesized in this study, analogues accommodate substituted tetrahydropyran moiety at their N-9 position 3-9, and the one with a promising IC 50 value against Huh7 (5.4 μM) is 6-(4-phenoxyphenyl)-9-(tetrahydropyran-2-yl)-9H-purine (9) .
Analyzing the data presented in bearing a 4-tert-butylphenyl substituent at C-6 position of the purine, was active derivative with greater potency against Huh7 cell line than 5-FU and Fludarabine. The After 72 h of incubation, SRB assays were generated and the cell death percentages were calculated in comparison with DMSO-treated wells.
